Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> MutationCaroline Robert, Paolo A. Ascierto, Georgina V. Long et al.|New England Journal of Medicine|2014Cited by 5.3k
Nivolumab plus Ipilimumab in Advanced MelanomaJedd D. Wolchok, Mario Sznol, Harriet M. Kluger et al.|New England Journal of Medicine|2013Cited by 4.2k
Metabolomic adaptations and correlates of survival to immune checkpoint blockadeHaoxin Li, Marios Giannakis, David F. McDermott et al.|Nature Communications|2019Cited by 222
irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical TrialJean‐Christophe Pignon, Sabina Signoretti, Opeyemi A. Jegede et al.|Clinical Cancer Research|2019Cited by 121
Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanomaGeorgina V. Long, Caroline Robert, Victoria Atkinson et al.|Journal of Translational Medicine|2015Cited by 53